Core Viewpoint - Jinxin Fertility (01951) reported a significant decline in financial performance, with a revenue drop of 10.75% year-on-year and a shift from profit to loss for shareholders, indicating challenges in the fertility services market in China [1] Financial Performance - Revenue for the six months ending June 30, 2025, was 1.289 billion RMB, down 10.75% year-on-year [1] - Shareholder loss amounted to 1.04 billion RMB, compared to a profit of 190 million RMB in the same period last year, marking a significant turnaround [1] Contributing Factors - A decrease of approximately 8.3% in OPU cycles contributed to the revenue decline [1] - The proportion of IUI patients among ARS patients increased by about 10.04%, with IUI typically costing 80% to 85% less than IVF, impacting overall revenue [1] - Average single-cycle prices fell by 7% to 8% due to adjustments in national medical insurance [1] - A 24% decline in traditional childbirth volumes, driven by lower fertility willingness in China, led to reduced obstetric and related revenues [1] - The company has initiated new departments and businesses, which have contributed to revenue in those areas [1]
港股异动 | 锦欣生殖(01951)绩后跌近4% 上半年同比盈转亏至10.4亿元